Rule 424(b)(3)
SEC File No.: 333-72829
PROSPECTUS
----------
12,349,094 Shares
SUNRISE TECHNOLOGIES INTERNATIONAL, INC.
Common Stock
_____________________________
We develop, manufacture and market laser systems for applications in
ophthalmology. Substantially all of our business activities, including
engineering and development, manufacturing, assembly and testing take place
at our facility in Fremont, California. All of the shares of common stock
offered in this Prospectus are being offered by the selling securityholders
in transactions on the Nasdaq National Market System or in privately
negotiated transactions. We will not receive any of the proceeds from the
sales.
Our common stock is traded on the Nasdaq National Market System under
the symbol "SNRS." On June 17, 1999, the closing price reported on the
Nasdaq National Market System was $10.5625 per share.
THIS INVESTMENT IN THE COMMON STOCK INVOLVES A HIGH DEGREE OF RISK.
YOU SHOULD PURCHASE SHARES ONLY IF YOU CAN AFFORD A COMPLETE LOSS. SEE
"RISK FACTORS" BEGINNING ON PAGE 2.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities.
They have not determined if this Prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
_____________________________
The date of this Prospectus is June 18, 1999
<PAGE>
TABLE OF CONTENTS
PROSPECTUS
Page
----
ABOUT SUNRISE . . . . . . . . . . . . . . . . . . . . . . . . 1
RISK FACTORS. . . . . . . . . . . . . . . . . . . . . . . . . 2
FORWARD-LOOKING STATEMENTS. . . . . . . . . . . . . . . . . . 8
USE OF PROCEEDS . . . . . . . . . . . . . . . . . . . . . . . 9
SELLING SECURITYHOLDERS . . . . . . . . . . . . . . . . . . . 9
PLAN OF DISTRIBUTION. . . . . . . . . . . . . . . . . . . . . 14
EXPERTS . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
LEGAL MATTERS . . . . . . . . . . . . . . . . . . . . . . . . 15
INDEMNIFICATION . . . . . . . . . . . . . . . . . . . . . . . 15
WHERE YOU CAN FIND MORE INFORMATION . . . . . . . . . . . . . 16
INCORPORATION OF INFORMATION WE FILE WITH THE SEC . . . . . . 16
<PAGE>
ABOUT SUNRISE
At Sunrise Technologies International, Inc., we develop, manufacture
and market laser systems for applications in ophthalmology. Substantially
all of our business activities, including engineering and development,
manufacturing, assembly and testing, take place at our facility in Fremont,
California.
Since mid-1992, we have focused a significant portion of our efforts
on engineering and development of our holmium laser corneal shaping
process. This process, known as laser thermal keratoplasty or LTK, treats
refractive errors of the eye, such as farsightedness and age-related loss
of near focusing ability. The LTK system is based upon patented technology
acquired in our acquisitions of in-process technology from Laser Biotech,
Inc. and Emmetropix Corporation in 1992. Our LTK system is currently
undergoing premarket clinical studies in the United States as required by
the Food and Drug Administration. Prior to this time, we were primarily a
developer and manufacturer of dental laser systems.
Our working capital is seriously depleted due to our substantial
losses in the past seven years. Sales of our existing ophthalmic products
at current levels will not be sufficient to sustain the continued
development and regulatory licensing of the laser thermal keratoplasty
system. We have been able to raise additional working capital for all
aspects of our business through the private placement of our common stock
and convertible notes with warrants.
We raised approximately $3,700,000 in the form of promissory notes
with warrants in 1997, approximately $9,300,000, net of offering costs, in
the form of promissory notes with warrants in January 1998, approximately
$11,800,000, net of offering costs, from the sale of common stock in
December 1998 and $10,000,000, net of offering costs, in the form of
promissory notes with warrants in January 1999.
Sunrise Technologies International, Inc. was incorporated in 1987
under the laws of the State of California and was reincorporated in 1993
under the laws of the State of Delaware. Our principal executive offices
are located at 3400 West Warren Avenue, Fremont, California 94538;
telephone (510) 623-9001.
1
<PAGE>
RISK FACTORS
This offering involves a high degree of risk. You should carefully
consider the risks described below and the other information contained in
this Prospectus before deciding to invest in shares of our common stock.
WE HAVE SUSTAINED LOSSES IN THE PAST AND WE EXPECT TO REPORT LOSSES IN THE
FUTURE
We have incurred substantial losses that have depleted our working
capital and reduced our stockholders' equity. In addition, we expect that
our business will continue to be a significant consumer of cash. Unless and
until the FDA approves the domestic sale of our LTK system for performing
laser thermal keratoplasty, our revenues will not be sufficient to cover
our operating costs. We filed the premarket approval application for low
hyperopia with the FDA on December 14, 1998. On January 28, 1999, the FDA
determined that the premarket approval application is suitable for filing.
The premarket approval application is scheduled for review at the July 22-
23 meeting of the FDA. We do not expect FDA approval of our premarket
approval application, however, until the second half of 1999, at the
earliest.
We funded our negative cash flows during 1996, 1997 and 1998 by the
sale of additional equity and convertible debt with warrants. At
December 31, 1997, our cash and cash equivalents were approximately
$1,958,000. At December 31, 1998, after consummation of the offering of
promissory notes with warrants in January 1998 (approximate net proceeds of
$9,300,000) and the sale of common stock in December 1998 (approximate net
proceeds of $11,800,000), our cash and cash equivalents were approximately
$9,889,000. Notwithstanding the proceeds of the offering of promissory
notes with warrants in January 1999, we may be required to raise additional
working capital during 1999 to fund our activities for late 1999 and
beyond. There can be no assurance that additional funds can be raised on
terms acceptable to us, if at all. Any additional equity or debt offerings
will dilute the holdings of our stockholders.
We expect to report operating losses during 1999. The losses will
come primarily from the expenses of the FDA approval process and underlying
clinical studies related to the LTK system. We will not have any domestic
revenues from this product line unless and until we obtain the FDA
approval. Our international revenues will not be sufficient to cover the
cost of the approval process or our general operating expenses.
NO ASSURANCE FUTURE CAPITAL WILL BE AVAILABLE TO US; ADDITIONAL CAPITAL
WILL DILUTE THE HOLDINGS OF OUR STOCKHOLDERS
Our stockholders have no preemptive rights. If we:
1. commence a subsequent public or private offering of common
stock, convertible debt, or preferred stock; or
2. issue securities to consultants or other parties providing
goods or services to us in lieu of or in addition to cash consideration,
our stockholders, who may not participate in any future stock issuance,
will experience dilution of their equity investment. At this time, we
cannot determine the potential dilution to our stockholders.
We cannot assure that additional financing will be available, or if
available, that it will be available on terms favorable to our
stockholders. If funds are not available to satisfy our short-term and
long-term operating requirements, we may limit or suspend our operations in
the entirety or, under certain circumstances, seek protection from
creditors. Our recent debt and equity offerings contained terms adverse to
our then existing stockholders, with stock sales prices below the then
market price of the common stock, convertible debt issued with interest
rates above the prime rate of interest and warrants granted to investors
without any substantial cash consideration to the Company. We believe that
2
<PAGE>
future financings undertaken prior to the commencement of sales of the LTK
system in the United States may contain terms that could result in similar
or more substantial dilution than that incurred by our stockholders from
the sales of equity and convertible debt with warrants we undertook during
1996, 1997, 1998 and earlier this year.
WE COULD EXPERIENCE SUBSTANTIAL DELAY IN RECEIVING OR MAY NOT RECEIVE THE
NECESSARY APPROVAL FROM THE FOOD AND DRUG ADMINISTRATION OF OUR PRE-MARKET
APPROVAL APPLICATION FOR OUR LASER THERMAL KEROTOPLASTY SYSTEM
The FDA and similar health authorities in foreign countries
extensively regulate our activities. The FDA regulates the LTK system under
the Food, Drug & Cosmetic Act, as a Class III medical device. Class III
medical devices must have a premarket approval application ("PMA") approved
by the FDA before commercial sales in the United States commence. The PMA
process (and underlying clinical studies) is lengthy, the outcome is
difficult to predict and the process requires substantial commitments of
our financial resources and our management's time and effort. Delays in
obtaining or failure to obtain required regulatory approvals or clearances
in the United States and other countries would postpone or prevent the
marketing of the LTK system and other devices. Consequently, delays would
impair our ability to generate funds from operations, which in turn would
have a material adverse effect on our business, financial condition and
results of operations.
In addition to analyzing the LTK system itself, the FDA may also
evaluate our public disclosures regarding the LTK system as part of the
review and approval process. In this regard, we received in early September
1998 a letter from the FDA stating that recent press releases contained
certain prohibited representations. The FDA did not require us to respond
to the letter. We no longer, however, include the items described in the
FDA letter in our public disclosures. We submitted our PMA on December 14,
1998 to the FDA, and we received notification from the FDA in a letter
dated January 28, 1999 that our application has been accepted for filing.
The PMA is scheduled for review at the July 22-23 meeting of the FDA.
We cannot be certain that we will be able to timely obtain, if at
all, the required approval of our PMA in the United States for our intended
uses of the LTK system, or for any other devices which we may seek
approvals or clearances. The FDA will subject us to pervasive and
continuing regulation for any products that we manufacture or distribute.
A new FDA regulation requires disclosure of the financial interests
of clinical investigators. This new regulation applies to all new PMAs
submitted on or after February 2, 1999. The purpose of this new regulation
is to assist the FDA in determining if, and to what extent, the clinical
studies supporting a marketing application may have been subject to
investigator bias. Some of our current 11 clinical investigators of the LTK
system have financial interests in us that meet the threshold for
disclosure under this new FDA regulation. It is not possible to predict,
however, what impact, if any, the disclosure of these interests would have
on the FDA's review of the PMA we submitted for the LTK system.
We received a CE (European Community) Mark of approval on our LTK
device that allows us to sell the device in these countries. In addition to
the CE Mark, however, some foreign countries may require separate
individual foreign regulatory clearances. Although we have sold our
products in approximately 15 countries, sales of the LTK system require
rigorous regulatory approvals before we can sell them in the United States
and certain other countries. We cannot assure that we will be able to
obtain regulatory clearances for our products in the United States or other
foreign markets.
3
<PAGE>
WE DEPEND ON THE LTK SYSTEM AND MARKET ACCEPTANCE OF THAT SYSTEM IS UNCLEAR
We intend to continue to concentrate our efforts primarily on the
development of the LTK system and will be dependent upon the successful
development of that system to generate revenues. We have not yet
commercially introduced the LTK system in the United States. There can be
no assurance that if approved by the FDA, the ophthalmic community or the
general population will accept the LTK system as an alternative to existing
methods of treating refractive vision disorders. Many ophthalmologists may
have already invested significant time and resources in developing
expertise in other corrective ophthalmic techniques. Acceptance of the LTK
system may be affected adversely by
. its costs,
. concerns related to its safety and efficacy,
. the general resistance to use of laser products on the eye,
. the effectiveness of alternative methods of correcting
refractive vision disorders,
. the lack of long-term follow-up data, or
. the possibility of unknown side effects.
Promotional efforts by suppliers of products or procedures which are
alternatives to the LTK system, including eyeglasses, contact lenses and
laser and non-laser surgical procedures, may also adversely affect the
marketplace for the LTK system. Any failure to achieve broad market
acceptance of the LTK system will have a material adverse effect on our
business, financial condition and results of operations.
ONLY LIMITED CLINICAL DATA ABOUT THE LONG-TERM SAFETY AND EFFICACY OF THE
LTK SYSTEM IS CURRENTLY AVAILABLE AND WE MAY BE REQUIRED TO UNDERTAKE
FURTHER TESTING
We have developed limited clinical data on the safety and efficacy of
the LTK system in correcting hyperopia (farsightedness) and related long-
term data. The FDA has not yet determined whether the LTK system will prove
to be safe or effective for the predictable and reliable treatment of
hyperopia or other common vision problems. Potential complications and
side effects reported in studies to date from the use of the LTK system
include
. mild foreign body sensation,
. temporary increased light sensitivity,
. modest fluctuations in refractive capabilities during healing,
. unintended over or under-corrections,
. regression of effect, and
. induced astigmatism.
We cannot assure that long-term safety and efficacy data when
collected will be consistent with the clinical trial results previously
obtained or will demonstrate that the LTK system can be used safely and
successfully to treat hyperopia in a broad segment of the population on a
long-term basis. The FDA may require the Company to conduct further testing
of the LTK system, thereby delaying the Company's efforts to generate
revenue, or limit the scope of the FDA approval, thereby limiting the
market for the LTK system.
4
<PAGE>
OUR PRODUCT EMPLOYS PROPRIETARY TECHNOLOGY AND THIS TECHNOLOGY MAY INFRINGE
ON THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES
We hold United States process and apparatus patents for the use of
holmium lasers in non-destructive cornea shaping. Other parties, however,
hold process and apparatus patents relating to shaping the cornea with
holmium lasers. Generally, an apparatus patent contains claims to a new and
useful machine or device. A process patent generally contains claims to a
new and useful process, art, or method, which may include a new use of a
known process, machine, manufacture, composition of matter, or material. We
believe that we are not infringing on any patents held by others. However,
if patents held by others were adjudged valid and interpreted broadly in an
adversarial proceeding, they could be deemed to cover one or more aspects
of our holmium laser corneal shaping systems, use of the LTK system, or
other procedures. Any claims for patent infringement could be time-
consuming, result in costly litigation, divert technical and management
personnel, or require us to develop non-infringing technology or enter into
royalty or licensing agreements. We cannot be certain that we will not be
subject to one or more claims for patent infringement, that we would
prevail in any such action, or that our patents will afford protection
against competitors with similar technology.
If a court determines that the LTK system infringes, directly or
indirectly, a patent in a particular market, the court may enjoin us from
making, using and selling such system. Furthermore, we may be required to
pay damages or obtain a royalty-bearing license, if available, on
acceptable terms. Alternatively, if a license is not offered or available,
we may be required to redesign those aspects of the LTK system held to
infringe, directly or indirectly, to avoid such infringement. Any redesign
could delay reintroduction of our products into certain markets, or may be
so significant as to be impractical. If redesign efforts were impractical,
we could be prevented from manufacturing and selling the infringing
products, which would have a material adverse effect on our business,
financial condition and results of operations.
A COMPONENT OF THE LTK SYSTEM MAY BE COVERED BY A PATENT OWNED OR LICENSED
BY A PARTY UNRELATED TO US WHICH MAY CAUSE US TO REDESIGN THE LTK SYSTEM,
WHICH COULD DELAY COMMERCIALIZATION
A component of the LTK delivery system is possibly covered by a
patent owned by the University of Miami or licensed to another party. We
believe that we will be able to conclude a satisfactory arrangement with
the University of Miami or its licensee. If, however, we are unable to
reach a successful agreement, we may have no rights to the component of the
delivery system presently configured in the LTK system. If we are forced
to redesign the LTK system, such redesign efforts could be time consuming,
expensive and prolong FDA review.
A SIGNIFICANT NUMBER OF OUR SHARES ARE ELIGIBLE FOR SALE AND THEIR SALE
COULD DEPRESS THE MARKET PRICE OF OUR STOCK
Sales of substantial amounts of our common stock (including shares
issued upon exercise of outstanding options and warrants and shares issued
upon conversion of convertible notes) in the public market could depress
the market price of our common stock. As of June 15, 1999, we had
43,880,976 shares outstanding and 9,932,391 shares reserved for issuance
upon exercise of options and warrants or conversion of convertible notes.
5
<PAGE>
LACK OF AVAILABILITY OF KEY SYSTEM COMPONENTS COULD RESULT IN DELAYS,
INCREASED COSTS, OR COSTLY REDESIGN OF OUR PRODUCT
Although some of the parts and components used by us in producing our
products are available from multiple sources, we currently purchase most of
our components from a single source in an effort to obtain volume
discounts. Lack of availability of any of these parts and components could
result in production delays, increased costs, or costly redesign of our
products. We continually evaluate ways to minimize any impact to our
business from any potential part or component shortage through inventory
stockpiling and design changes to afford opportunities for multiple sources
of supply for these essential components. Any loss of availability of an
essential system component could result in a material adverse change to our
business, financial condition and results of operations.
THE SUCCESS OF COMPETITIVE PRODUCTS COULD HAVE AN ADVERSE AFFECT ON OUR
BUSINESS
The vision correction industry is intensely competitive. The
significant competitive factors in the industry include
. price,
. convenience,
. success relative to vision correction,
. acceptance of new technologies,
. patient satisfaction, and
. government approval.
Patients with hyperopia (farsightedness) can achieve vision
correction with eyeglasses, contact lenses and possibly with other
technologies and surgical techniques currently under development, such as
. corneal implants,
. human lens replacement,
. intra-ocular implantable contact lenses, and
. surgery using different types of lasers.
The success of any competing alternative to the LTK system for
treating hyperopia could have a material adverse effect on our business,
financial condition and results of operations. Most of our competitors have
substantially greater financial capabilities for product development and
marketing than we do. These financial capabilities enable our competitors
to market their products or procedures to the consumer and to the
ophthalmic community in a more effective manner.
The excimer laser is the dominant laser used for the treatment of
refractive disorders. In the United States, VISX, Inc. and Summit
Technologies, Inc. are the leading manufacturers of excimer refractive
surgical systems. We believe the LTK system offers several distinct
advantages over the use of excimer lasers for treating hyperopia, including
ease of use and decreased invasiveness. Both VISX and Summit, however, have
significantly greater financial resources than we do and have received FDA
approval for their respective excimer laser products for treating myopia
(nearsightedness) and astigmatism. In addition, certain of our competitors,
including Summit, have developed LTK devices for the treatment of
hyperopia. Furthermore, one of our competitors, VISX, has received FDA
approval to treat hyperopia in the United States with its excimer laser.
6
<PAGE>
Neither the Summit excimer laser products nor the Summit LTK devices
are currently approved for treating hyperopia in the United States.
Furthermore, Summit discontinued its clinical trials for treating hyperopia
with its holmium laser system in 1996. Any alternative treatment offered by
VISX or Summit, however, will have a competitive advantage. They are
promoting their excimer laser products for correcting myopia
(nearsightedness) using lasers and have established a base of customers
that are currently using their products.
WE ARE DEPENDENT ON OUR MANAGEMENT AND KEY PERSONNEL TO SUCCEED
Our principal executive officers and key personnel have extensive
experience with our LTK system, the research and development efforts needed
to bring the LTK system to market and the development of a marketing and
sales program to be utilized in connection with the sales program to be
implemented when the necessary FDA approval is received. The loss of the
services of any of our executive officers or other key personnel, or our
failure to attract and retain other skilled and experienced personnel on
acceptable terms, could have a material adverse effect on our ability to
continue the FDA trials related to the LTK system and subsequent sales and
marketing efforts. This could have an adverse impact on our business and
related financial condition.
LOSS OF DENTAL REVENUES SEVERELY REDUCED OUR REVENUES
Before the sale of our dental assets in June 1997, the sale of our
dental laser and air abrasive products constituted the majority of our
revenues. These sales represented 98% and 69% of our revenues in 1996 and
1997, respectively. By selling the dental assets, we lost a significant
source of continued revenue, although the dental assets made a negative
contribution to our financial results.
THE MARKET PRICE OF OUR STOCK HAS HISTORICALLY BEEN VOLATILE
The volatility of our common stock imposes a greater risk of capital
losses on stockholders as compared to less volatile stocks. In addition,
such volatility makes it difficult to ascribe a stable valuation to a
stockholder's holdings of our common stock. Factors such as announcements
of technological innovations or new products by our competitors, changes in
domestic or foreign governmental regulations or regulatory approval
processes, developments or disputes relating to patent or proprietary
rights and public concern as to the safety and efficacy of the procedures
for which the LTK system is used, have and may continue to have a
significant impact on the market price of our common stock. Moreover, the
possibility exists that the stock market (and in particular the securities
of technology companies such as ours) could experience extreme price and
volume fluctuations unrelated to operating performance.
THE FAILURE OF KEY SUPPLIERS AND OUR PRODUCTS TO BE YEAR 2000 COMPLIANT
COULD NEGATIVELY AFFECT OUR BUSINESS
We are aware of the issues associated with computer systems
programming code as the millennium (year 2000) approaches. The "Year 2000"
problem is pervasive and complex because virtually every computer operation
will be affected in the same way by the rollover of the two-digit year
value to "00." The issue is whether computer systems will properly
recognize date-sensitive information when the year changes to 2000. Systems
that do not properly recognize such information could generate erroneous
data or cause a system to fail.
7
<PAGE>
We are utilizing both internal and external resources to identify,
correct or reprogram, and test our systems for Year 2000 compliance. As of
March 31, 1999, the estimated costs of these reprogramming efforts have
been approximately $250,000. We expect that the remaining costs to complete
these reprogramming efforts will be less than $100,000. We anticipate that
we will complete all of our reprogramming efforts by August 31, 1999,
allowing adequate time for testing. This process includes obtaining
confirmations from our primary vendors that they have developed (or are
developing) plans to address processing of transactions in the year 2000.
We expect to obtain these confirmations in writing prior to July 31, 1999.
There can be no assurance, however, that the systems of other companies, on
which our systems rely, will also be converted in a timely manner.
Moreover, we cannot be certain that any such failure to convert by another
company would not have a material adverse effect on our business, financial
conditions or results of operations.
We believe that we do not have a Year 2000 problem with the products
we have sold in the past. We have not performed, however, an extensive
review of these systems, and we are unlikely to be able to complete a
review before January 1, 2000. In addition, we are designing a new product
to replace our existing LTK system that will properly recognize date-
sensitive information for the year 2000 and beyond. Although we plan to
perform extensive testing of our new product, we cannot be certain that the
new system will function properly until we deploy it in the field and
subject it to extensive use. Any malfunction of a deployed system could
have a material adverse effect on our business, financial condition or
results of operations.
We are not expecting to have a material accounts receivable exposure
or significant amount of revenues with any one customer after December 31,
1999. Therefore, we are not pursuing verification of customer Year 2000
compliance at this time. Any failure to pay in a timely manner, or place
orders for our products, by a significant number of individual customers or
by a customer with a material accounts receivable balance, due to Year 2000
compliance issues would have material adverse effects on our business,
financial condition or results of operations.
We are currently developing a contingency plan to evaluate business
disruption scenarios, coordinate the establishment of Year 2000 contingency
plans and identify and implement the strategies. We expect to complete this
detailed contingency plan by July 31, 1999.
FORWARD-LOOKING STATEMENTS
Sunrise Technologies International, Inc. makes statements in this
Prospectus and the documents incorporated by reference that are considered
forward-looking statements within the meaning of the Securities Act of 1933
and the Securities Exchange Act of 1934. The Private Securities Litigation
Reform Act of 1995 contains the safe harbor provisions that cover these
forward-looking statements. We are including this statement for purposes
of complying with these safe harbor provisions. We base these forward-
looking statements on our current expectations and projections about future
events. These forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties and assumptions
including, among other things:
. continued losses and cash flow deficits;
. the continued availability of financing in the amounts, at the
times and on the terms required to support our future business;
. inability to receive appropriate regulatory approval from the
Food and Drug Administration;
8
<PAGE>
. uncertain market acceptance of our products;
. safety, efficacy and patent concerns regarding our products and
technology;
. competition;
. reliance on key personnel; and
. unforeseen operational difficulties and financial losses due to
year 2000 computer problems.
Words such as "expect," "anticipate," "intend," "plan," "believe,"
"estimate" and variations of such words and similar expressions are
intended to identify such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Because of these risks, uncertainties and assumptions, the forward-looking
events discussed or incorporated by reference in this document may not
occur.
USE OF PROCEEDS
We will not receive any proceeds from the sale of the shares of
common stock by the selling securityholders.
SELLING SECURITYHOLDERS
The shares of common stock offered herein represent shares:
. acquired by the individuals and entities listed below through
private placements of common stock in December 1998;
. that had been or may be acquired upon conversion of promissory
notes or exercise of warrants issued by us in private placements in March
1997, January 1998 and January 1999; and
. that may be acquired upon exercise of warrants issued to
certain of our executive officers, consultants and non-employee directors.
Absent registration under the Securities Act, the shares of common
stock offered herein are subject to certain limitations on resale. The
Registration Statement of which this Prospectus forms a part has been filed
in satisfaction of certain registration rights we granted to the
individuals and entities listed below.
Certain of the individuals and entities listed below, Pennsylvania
Merchant Group and M.J. Meehan & Co., are, or are affiliated with, members
of the National Association of Securities Dealers, Inc. Pennsylvania
Merchant Group has engaged from time to time, and in the future
Pennsylvania Merchant Group and/or M.J. Meehan & Co. and/or their
respective affiliates may engage, in market-making activities with respect
to the common stock. Pennsylvania Merchant Group, M.J. Meehan & Co. and
their respective affiliates have engaged from time to time, and in the
future may engage, in purchase and sale transactions involving the common
stock, including transactions with other NASD member firms. The individuals
and entities listed below, including Pennsylvania Merchant Group and M.J.
Meehan & Co., and any participating broker or dealer may be deemed to be
"underwriters" within the meaning of the Securities Act. Any commissions,
discounts or concessions and any gain realized by a person deemed to be an
underwriter may be deemed to be underwriting compensation to such person.
From time to time since 1994, Pennsylvania Merchant Group has provided
financial advisor and investment banking services to us pursuant to
engagement and other agreements. Under such agreements, we have agreed to
indemnify Pennsylvania Merchant Group and certain of its affiliates and
employees from and against certain losses and liabilities.
9
<PAGE>
<TABLE>
The following table assumes that each of the individuals and entities listed below will sell all of the
common stock offered herein set forth opposite such individual or entity's name. However, one or more of the
individuals or entities listed below may sell only a portion or may sell none of the shares set forth opposite
such individual or entity's name.
<CAPTION>
Common Shares
Common Shares Number of Beneficially
Beneficially Owned Prior Shares Owned After the
to the Offering (1) Held of Offering (1)
------------------------- Record to be -------------------------
Number of Percent Sold in the Number of Percent
Shares of Class Offering Shares of Class
---------- ---------- ------------ ---------- ----------
<S> <C> <C> <C> <C> <C>
William M. Aden (2) 57,143 * 57,143 -- *
Drs. Alan B. Aker and Ann G.
Kasten-Aker (2) 1,774,807 4.2% 1,289,050 485,757 1.1%
Amanda Alton 1,000 * 1,000 -- *
Andrew Alton 1,000 * 1,000 -- *
Bob Alton 1,000 * 1,000 -- *
Carley Alton 2,000 * 2,000 -- *
David Alton 1,000 * 1,000 -- *
Jill Alton 1,000 * 1,000 -- *
Aragon Ventures LLC (2) 2,373,934 5.6% 2,305,200 68,734 *
Jay Alpha Arney, Alpha Group
Corporation 215,000 0.5% 215,000 -- *
Hank Asher 50,000 * 50,000 -- *
Charles H. Bechert IRA 60,000 * 60,000 -- *
Charles H. Bechert II, M.D. 30,000 * 30,000 -- *
Sandra C. Belmont 7,500 * 7,500 -- *
Harold P. Bernstein 50,000 * 50,000 -- *
David A. Brewer (2) 28,738 * 28,738 -- *
David C. Brown, M.D. (2) 2,342,341 5.5% 942,857 1,399,484 3.3%
Jeannie G. Cecka (2) 268,477 * 50,000 218,477 *
Lawton and Rhea Chiles (2) 171,429 * 171,429 -- *
Edward F. Coghlan (2) 125,000 * 125,000 -- *
Coutts (Jersey) Limited (2) 250,000 * 250,000 -- *
Allan R. Crevi and
James F. Sullivan, JTWROS 14,285 * 14,285 -- *
Arthur S. DeMoss Foundation 100,000 * 100,000 -- *
Alexander M. Eaton 14,500 * 14,500 -- *
Amir L. Ecker (2) 150,000 * 150,000 -- *
Amir L. Ecker IRA (2) 105,000 * 105,000 -- *
EDJ Limited (2) 30,000 * 30,000 -- *
Paul H. Ernest (2) 77,353 * 5,000 72,353 *
Jan Feldman 4,285 * 4,285 -- *
Gary J. and Susan O. Ferrentino 20,000 * 20,000 -- *
10
<PAGE>
Common Shares
Common Shares Number of Beneficially
Beneficially Owned Prior Shares Owned After the
to the Offering (1) Held of Offering (1)
------------------------- Record to be -------------------------
Number of Percent Sold in the Number of Percent
Shares of Class Offering Shares of Class
---------- ---------- ------------ ---------- ----------
Eric M. and Deborah K. Fogel,
JTWROS 20,000 * 20,000 -- *
Gregory A. and Carol G.
Frankenfield, JTWROS
(2) 7,000 * 4,000 3,000 *
Jerre M. Freeman, M.D. 28,571 * 28,571 -- *
J. L. Gayton, M.D.
J.L. Gayton, M.D. PC,
401(k) Profit Sharing Plan 14,285 * 14,285 -- *
J.L. Gayton IRA (2) 71,428 * 71,428 -- *
James P. Gills, M.D. 285,714 * 285,714 -- *
Frank Goes, M.D. 28,571 * 28,571 -- *
George H. Griffin (2) 924,314 2.2% 575,714 348,600 *
Robert A. Haddad (2) 158,712 * 50,000 108,712 *
The Haddad Family Trust
(2) 57,477 * 57,477 -- *
Hanabusa Investments, Inc.
(2) 28,738 * 28,738 -- *
David I. Herbst 6,000 * 6,000 -- *
Don S. and Mary R. Hershman, JTWROS 3,000 * 3,000 -- *
William Wells Hutchins 25,000 * 25,000 -- *
Mitchell A. Jackson, M.D. 25,714 * 25,714 -- *
Maurice John 14,285 * 14,285 -- *
Gerald Jones 1,000 * 1,000
Dave Kenly 15,000 * 15,000 -- *
Erin Kenly 1,000 * 1,000 -- *
Steve Kenly 4,000 * 4,000 -- *
Joseph D. Koenig (2) 165,404 * 50,000 115,404 *
Thomas Kohnen (2) 5,000 * 5,000 -- *
Manus C. Kraff (2) 407,849 * 287,384 120,105 *
Stephen J. Landes 3,000 * 3,000 -- *
Susan Smith Lorigan Trustee UTD
7/21/97 FBO Susan Smith Lorigan
1997 Revocable Trust 7,766 * 7,766 -- *
Mary Losty (2) 27,000 * 27,000 -- *
Paul M. Malin (2) 258,373 * 30,000 228,373 *
Robert Gale Martin (2) 200,000 * 200,000 -- *
Robert Maynor 14,285 * 14,285 -- *
Peter J. McDonnell (2) 5,000 * 5,000 -- *
Scott McQueen (2) 10,000 * 10,000 -- *
M.J. Meehan & Co. LLC (2) 86,215 * 86,215 -- *
11
<PAGE>
Common Shares
Common Shares Number of Beneficially
Beneficially Owned Prior Shares Owned After the
to the Offering (1) Held of Offering (1)
------------------------- Record to be -------------------------
Number of Percent Sold in the Number of Percent
Shares of Class Offering Shares of Class
---------- ---------- ------------ ---------- ----------
Terence S. Meehan 20,000 * 20,000 -- *
Dr. Salomon and Flor Melgen,
Tenancy by the Entirety (2) 1,123,893 2.6% 1,003,336 120,557 *
Jeffrey Meloche (2) 85,714 * 85,714 --
Joe Meloche (2) 85,714 * 85,714 -- *
Hugo Nano (2) 5,000 * 5,000 -- *
Michael M. Nesbitt 20,000 * 20,000 -- *
Daniel J. O'Connor (2) 28,571 * 28,571 -- *
Pacific National Bank Custodian for
benefit of Richard T. VanRyne IRA 79,625 * 57,477 22,168 *
Joel Packer 14,286 * 14,286 -- *
Pennsylvania Merchant Group (2) 227,442
Joseph Piccirilli 14,286 * 14,286 -- *
Porter Partners, L.P. (2) 141,000 * 141,000 -- *
Emanuel S. Rosen (2) 5,000 * 5,000 -- *
Leonard Roytman (2) 50,000 * 25,000 25,000 *
Donald Sanders, M.D. 668,062 1.6% 285,714 382,348 *
William R. Schlichtemeier, M.D. 14,285 * 14,285 -- *
Joseph W. Shaffer 50,000 * 50,000 -- *
Donald R. Sanders, IRA, CIBC
Oppenheimer Corp. as Trustee
(2) 1,105,766 2.6% 945,766 160,000 *
Sol-Rich Capital Group LLC 28,571 * 28,571 -- *
Regina Stancel (2) 205,215 * 86,215 119,000 *
Douglas L. Steele, MD TTEE
a Prof. Corp. Profit Sharing
Plan UAP 14,285 * 14,285 -- *
Byron A. and Caroline B. Stratas 124,285 * 124,285 -- *
C. Russell Trenary, III (2)
Richard T. VanRyne (2) 486,375 1.1% 452,000 34,375 *
Rogelio Villareal (2) 5,000 * 5,000 -- *
M. Jay Walkingshaw 14,300 * 14,300 -- *
Daniel W. Welch and
Marcia McBride Welch 60,000 * 60,000 -- *
Joyce P. Wexler 3,000 * 3,000 -- *
Dennis L. Williams, M.D. 92,857 * 92,857 -- *
Bill Wimberly 2,000 * 2,000 -- *
Carolyn Wittenbraker 7,857 * 7,857 -- *
12
<PAGE>
Common Shares
Common Shares Number of Beneficially
Beneficially Owned Prior Shares Owned After the
to the Offering (1) Held of Offering (1)
------------------------- Record to be -------------------------
Number of Percent Sold in the Number of Percent
Shares of Class Offering Shares of Class
---------- ---------- ------------ ---------- ----------
Allan Wulfstat 3,000 * 3,000 -- *
Irwin L. Zalcberg 20,000 * 20,000 -- *
Irwin L. Zalcberg Profit Sharing
Plan Dtd. 8/15/84 Irwin Zalcberg
TTEE 14,286 * 14,286 -- *
<FN>
________________
* Less than one percent.
(1) Determined as of June 14, 1999.
(2) Some or all of the shares being registered for this investor are currently represented by warrants
convertible into our common stock at the sole discretion of the selling securityholder.
13
</TABLE>
<PAGE>
Effective as of April 22, 1999, the payment-in-kind notes we issued
in 1997 were converted into approximately 1,250,000 shares of our common
stock, which shares are included in this registration.
Included in the shares being registered are the following outstanding
warrants:
Number of
Warrants Exercise Price Expiration Date
--------- -------------- ---------------
304,286 $1.000 02/26/02
614,071 $1.000 03/07/02
337,857 $1.000 03/20/02
7,500 $1.000 11/25/02
35,000 $3.690 11/25/02
1,640,000 $3.000 01/15/03
150,000 $4.375 10/31/03
148,950 $0.010 01/01/04
75,000 $4.690 01/01/04
402,000 $5.310 01/01/04
430,000 $5.940 01/01/04
50,000 $5.940 01/22/04
150,000 $4.313 01/22/04
---------
Total 4,344,664
=========
PLAN OF DISTRIBUTION
Some or all of the common stock offered herein may be offered for
sale and sold from time to time by the individuals and entities listed
above in the over-the-counter market (or any national securities exchange
or interdealer quotation system on which the common stock may then be
listed), or in privately negotiated transactions (which may include block
transactions) or otherwise. In addition, the individuals and entities
listed above may engage in short sales and other transactions in the common
stock or derivatives thereof, and may pledge, sell, deliver or otherwise
transfer the common stock offered herein in connection therewith. This
Prospectus may be used by the individuals and entities listed above or by
any broker-dealer who may participate in sales of the common stock offered
herein. Participating broker-dealers may act as agents or principals or
both and may receive commissions, discounts or concessions in connection
with sales or other transfers of the common stock offered herein. We have
not entered into any agreements or arrangements relating to the sale of the
common stock offered herein.
We have agreed to pay the expenses of registering the common stock
offered herein on behalf of the individuals and entities listed above,
other than broker-dealer commissions, discounts or concessions and any
legal fees incurred by the individuals and entities listed above in
connection with sales of the common stock offered herein. The Company and
the individuals and entities listed above have agreed to indemnify each
other against certain liabilities, including liabilities under the
Securities Act.
EXPERTS
The consolidated statements of operations, stockholders' equity and
cash flows of the Company appearing in the Company's Annual Report (Form
10-K) for the year ended December 31, 1996, have been audited by Ernst &
Young LLP, independent auditors, as set forth in their report thereon
(which contains an explanatory paragraph describing conditions that raise
substantial doubt about the Company's ability to continue as a going
concern) included therein and incorporated herein by reference. Such
consolidated statements of operations, stockholders' equity and cash flows
are incorporated herein by reference in reliance upon such report given
upon the authority of such firm as experts in accounting and auditing.
14
<PAGE>
The consolidated balance sheets as of December 31, 1998 and 1997 and
the consolidated statements of operations, stockholders' equity and cash
flows for each of the two years in the period ended December 31, 1998,
incorporated by reference in this Registration Statement, have been
incorporated herein in reliance on the report of PricewaterhouseCoopers
LLP, independent accountants, given on the authority of that firm as
experts in accounting and auditing.
LEGAL MATTERS
Certain legal matters with respect to the validity of the Offered
Shares will be passed upon for the Company by Holleb & Coff, Chicago,
Illinois. Eric M. Fogel, a partner with the law firm of Holleb & Coff, is
presently the Secretary of the Company and certain of such firm's partners
own shares of common stock, some of which are the selling securityholders.
INDEMNIFICATION
Section 102(b)(7) of the General Corporation Law of the State of
Delaware grants corporations the right to limit or eliminate the personal
liability of their directors in certain circumstances in accordance with
provisions therein set forth. The Certificate of Incorporation of the
Company contains a provision eliminating director liability to the Company
and its stockholders for monetary damages for breach of fiduciary duty as a
director. The provision does not, however, eliminate or limit the personal
liability of a director:
. for any breach of such director's duty of loyalty to the
Company or its stockholders;
. for acts or omissions not in good faith or which involve
intentional misconduct or a knowing violation of law;
. under the Delaware statutory provision making directors
personally liable, for improper payment of dividends or improper stock
purchases or redemptions; or
. for any transaction from which the director derived an improper
personal benefit.
This provision offers persons who serve on the Company's Board of
Directors protection against awards of monetary damages resulting from
breaches of their duty of care (except as indicated above). As a result of
this provision, the ability of the Company or a stockholder thereof to
successfully prosecute an action against a director for a breach of his
duty of care is limited. However, the provision does not affect the
availability of equitable remedies such as an injunction or rescission
based upon a director's breach of his duty of care. The SEC has taken the
position that the provision will have no effect on claims arising under
federal securities laws.
Section 145 of the Delaware law grants corporations the right to
indemnify their directors, officers, employees and agents in accordance
with the provisions therein set forth. The Company's By-laws provide that
the Company shall, subject to limited exceptions, indemnify its directors
and executive officers to the fullest extent not prohibited by the Delaware
Law. The Company's By-laws provide further that the Company shall have the
power to indemnify its other officers, employees and other agents as set
forth in the Delaware law. Such indemnification rights include
reimbursement for expenses incurred by such director, executive officer,
other officer, employee or agent in advance of the final disposition of
such proceeding in accordance with the applicable provisions of the
Delaware law.
15
<PAGE>
The Company has entered into agreements with certain of its directors
and officers pursuant to which the Company has agreed to indemnify such
directors and officers to the fullest extent permitted under applicable
law. In addition, the Company has purchased insurance containing customary
terms and conditions as permitted by law on behalf of its directors and
officers, which may cover liabilities under the Securities Act. Insofar as
indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the Company
pursuant to these provisions, or otherwise, the Company has been advised
that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable.
WHERE YOU CAN FIND MORE INFORMATION
We file reports, proxy statements and other information with the
Securities and Exchange Commission. Our SEC filings are also available
over the Internet at the SEC's web site at http://www.sec.gov. You may
also read and copy any document we file at the SEC's public reference rooms
in Washington, D.C., New York, New York and Chicago, Illinois. Please call
the SEC at 1-800-SEC-0330 for more information on the public reference
rooms.
INCORPORATION OF INFORMATION WE FILE WITH THE SEC
The SEC allows us to "incorporate by reference" the information we
file with them, which means:
. incorporated documents are considered part of the Prospectus;
. we can disclose important information to you by referring you
to those documents; and
. information that we file with the SEC will automatically update
and supersede the Prospectus.
We are incorporating by reference the documents listed below which
were filed with the SEC under the Exchange Act:
. Annual Report on Form 10-K for the year ended December 31,
1998, including the portions of our proxy statement, dated April 9, 1999,
incorporated by reference in such report;
. Annual Report on Form 10-K/A for the year ended December 31,
1998
. Current Report on Form 8-K, dated January 1, 1999;
. Current Report on Form 8-K, dated March 10, 1999;
. Current Report on Form 8-K, dated March 20, 1999;
. Current Report on Form 8-K, dated April 6, 1999;
. Current Report on Form 8-K, dated May 5, 1999;
. Quarterly Report on Form 10-Q for the quarter ended March 31,
1999; and
. Definitive proxy statement filed under Section 14 of the
Exchange Act in connection with the stockholders' meeting held on April 30,
1999.
We also incorporate by reference each of the following documents that
we will file with the SEC after the date of the Prospectus but before the
end of the offering:
. Reports filed under Sections 13(a) and (c) of the Exchange Act;
16
<PAGE>
. Definitive proxy or information statements filed under
Section 14 of the Exchange Act in connection with any subsequent
stockholders' meeting; and
. Any reports filed under Section 15(d) of the Exchange Act.
You may request a copy of these filings, at no cost, by contacting us
at the following address or phone number:
Sunrise Technologies International, Inc.
Attn: Ms. Sylvia Ward
Acting Controller
3400 West Warren Avenue
Fremont, California 94538
Tel: (510) 623-9001
http://www.sunrise-tech.com
You should rely only on the information incorporated by reference or
provided in this Prospectus or any supplement. We have not authorized
anyone else to provide you with different information. The selling
securityholders will not make an offer of these shares in any state where
the offer is not permitted. You should not assume that the information in
this Prospectus or any supplement is accurate as of any date other than the
date on the front of these documents.
This Prospectus is part of a Registration Statement we filed with the
SEC (Registration No. 333-72829).
17
<PAGE>
=======================================================================
12,349,094 Shares
SUNRISE TECHNOLOGIES INTERNATIONAL, INC.
Common Stock
----------
PROSPECTUS
----------
June 18, 1999
=======================================================================
